Ryo Dairiki

1.0k total citations
7 papers, 442 citations indexed

About

Ryo Dairiki is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Ryo Dairiki has authored 7 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Hepatology. Recurrent topics in Ryo Dairiki's work include RNA modifications and cancer (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Epigenetics and DNA Methylation (2 papers). Ryo Dairiki is often cited by papers focused on RNA modifications and cancer (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Epigenetics and DNA Methylation (2 papers). Ryo Dairiki collaborates with scholars based in Japan, United States and United Kingdom. Ryo Dairiki's co-authors include Fumihito Miura, Yusuke Enomoto, Takashi Ito, Toshiyuki Nomura, Shinsuke Araki, Risa Miyashita, Osamu Nakanishi, Yusuke Nakayama, Misa Iwatani and Aiko Murai and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Ryo Dairiki

7 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryo Dairiki Japan 6 389 72 52 31 29 7 442
Lupin Jiang China 8 195 0.5× 95 1.3× 83 1.6× 12 0.4× 28 1.0× 12 352
Gabriele Migliorini United Kingdom 8 249 0.6× 76 1.1× 44 0.8× 4 0.1× 8 0.3× 10 342
Wentao Zeng China 10 332 0.9× 33 0.5× 252 4.8× 13 0.4× 9 0.3× 16 467
Stephen Arnovitz United States 9 224 0.6× 63 0.9× 44 0.8× 5 0.2× 18 0.6× 17 343
Valentina C. Sladky Austria 9 237 0.6× 41 0.6× 38 0.7× 32 1.0× 3 0.1× 11 331
Daniela Ulgiati Australia 13 167 0.4× 33 0.5× 29 0.6× 12 0.4× 3 0.1× 28 328
George Yam United States 4 289 0.7× 26 0.4× 31 0.6× 5 0.2× 8 0.3× 5 405
Ryan J. Quinton United States 6 167 0.4× 31 0.4× 69 1.3× 6 0.2× 4 0.1× 9 270
Linh Huynh Japan 6 259 0.7× 41 0.6× 39 0.8× 6 0.2× 7 0.2× 6 334
Laura Godfrey United States 8 319 0.8× 51 0.7× 40 0.8× 3 0.1× 17 0.6× 11 418

Countries citing papers authored by Ryo Dairiki

Since Specialization
Citations

This map shows the geographic impact of Ryo Dairiki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryo Dairiki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryo Dairiki more than expected).

Fields of papers citing papers by Ryo Dairiki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryo Dairiki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryo Dairiki. The network helps show where Ryo Dairiki may publish in the future.

Co-authorship network of co-authors of Ryo Dairiki

This figure shows the co-authorship network connecting the top 25 collaborators of Ryo Dairiki. A scholar is included among the top collaborators of Ryo Dairiki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryo Dairiki. Ryo Dairiki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Lee, Chung‐Han, Robert J. Motzer, M. Dror Michaelson, et al.. (2018). Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma. Annals of Oncology. 29. viii23–viii23. 2 indexed citations
2.
Finn, Richard S., Masatoshi Kudo, Ann‐Lii Cheng, et al.. (2018). Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. Annals of Oncology. 29. viii17–viii18. 21 indexed citations
3.
Makker, Vicky, Allen Lee Cohn, Matthew H. Taylor, et al.. (2018). Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.. Journal of Clinical Oncology. 36(15_suppl). 5597–5597. 5 indexed citations
4.
Finn, Richard S., Masatoshi Kudo, Ann‐Lii Cheng, et al.. (2017). Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 28. v617–v617. 11 indexed citations
5.
Ishikawa, Yoshinori, Megumi Morimoto, Akio Mizutani, et al.. (2017). Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication. Oncogenesis. 6(9). e377–e377. 26 indexed citations
6.
Araki, Shinsuke, Ryo Dairiki, Yusuke Nakayama, et al.. (2015). Inhibitors of CLK Protein Kinases Suppress Cell Growth and Induce Apoptosis by Modulating Pre-mRNA Splicing. PLoS ONE. 10(1). e0116929–e0116929. 91 indexed citations
7.
Miura, Fumihito, Yusuke Enomoto, Ryo Dairiki, & Takashi Ito. (2012). Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging. Nucleic Acids Research. 40(17). e136–e136. 286 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lupin Jiang Breakdown of academic impact, for papers by Gabriele Migliorini Breakdown of academic impact, for papers by Wentao Zeng Breakdown of academic impact, for papers by Stephen Arnovitz Breakdown of academic impact, for papers by Valentina C. Sladky Breakdown of academic impact, for papers by Daniela Ulgiati Breakdown of academic impact, for papers by George Yam Breakdown of academic impact, for papers by Ryan J. Quinton Breakdown of academic impact, for papers by Linh Huynh Breakdown of academic impact, for papers by Laura Godfrey
Rankless by CCL
2026